You are here

AusPAR: Galcanezumab

Related information


How to access a pdf or Word document

*Large file warning: Attempting to open large files over the Internet within the browser window may cause problems. It is strongly recommended you download this document to your own computer and open from there.

Australian Public Assessment Report

2 October 2019
AusPAR Details
AusPAR
Active Ingredient
Galcanezumab
Product Name
Emgality
Sponsor
Eli Lilly Australia Pty Limited
Submission Number
PM-2018-00780-1-1
Submission Type
New biological entity
Decision
Approved
AusPAR Date
10 September 2019
Publication Date

2 October 2019